SCOPE
A theoretical, guiding strategy to use synergistic, combinations of metabolic acting therapies with a specific Ketovore (enhanced Ketogenic formula) controlled diet
About
The Ketovore Metabolic Research Institute pursues independent laboratory research, with a primary emphasis on the relationship of enhanced ketogenic metabolism and disease.
Particularly, what we are looking into now, is to learn if we can produce via supplementary auxiliary therapy with 6-Diazo-5-oxo-L-norleucine (D.O.N.), similar metabolic effects that are seen already with the use of Oxaloacetate, using a murine model.
Thus, we will start with a limited volume of substrate, in accordance with establishing some first sequence preliminary data, via small group testing, with natural, non-mutated mice.
Based on these initial results, a 45-day trial of a 4-arm murine group of 12 Wild Types each, in an open label crossover study (inclusive of two-week blackout period) with a presence standard of normal hemoglobin A1c (5.6. or below, with no documented pathologies), consuming an intervention of either oral ascorbic acid bound oxaloacetate, or, D.O.N., in combination with a proportional nutritional intervention composed of ad libitum feeding (versus restricted feeding) of either Teklad NIH-07 Standard Chow or Teklad TD.963559(A) enhanced Ketogenic formula.
What we are looking for are statistically significant serum/imaging variations (measured at 14-day/2-week intervals) from baseline in:
Glucose – Glucagon – Insulin – Glutamine – GDH –
Leptin - GhrelinBetahydroxybutyrate- Lactate –
Body Composition as evaluated by Florescent Cell Imaging
Furthermore, our research study will follow established oral dosing regimen for D.O.N., in a mouse model, at 7.4–40.7 mg/m2/dose.